MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$185,498
Free Cash flow
-$489,502
Unit: Dollar
Positive Cash Flow Breakdown
    • Net proceeds from notes payable ...
    • Accounts payable
    • Non-cash interest expense
    • Others
Negative Cash Flow Breakdown
    • Accounts receivable, net
    • Purchases of property and equipm...
    • Deferred revenue
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-277,601
-618,466
-578,480
-537,919
Depreciation expense
26,198
22,256
23,912
23,148
Stock-based compensation
41,490
23,527
23,527
19,915
Non-cash interest expense
113,910
174,635
-
-
Provision for credit losses
0
0
50,000
28,876
Provision for inventory obsolescence
0
0
10,252
0
Vendor expense settled in shares
21,000
18,000
18,000
18,000
Gain on settlement of accounts payable
-
-
0
-
Amortization of operating lease right of use assets
19,402
18,942
18,498
18,073
Accounts receivable, net
293,902
312,002
-40,585
360,688
Inventory, net
20,981
34,776
22,386
35,811
Prepaid expenses and other current assets
-27,187
78,699
-38,468
43,307
Accounts payable
177,865
-50,848
-55,576
178,775
Accrued expenses
25,757
99,497
102,900
76,338
Deferred revenue
-77,941
-27,941
-75,000
-75,000
Operating lease liabilities
-18,859
-18,397
-17,346
-16,916
Net cash provided by (used in) operating activities
-236,475
-784,272
-422,646
-706,516
Purchases of property and equipment
253,027
847
43,205
0
Net cash used in investing activities
-253,027
-847
-43,205
0
Net proceeds from issuance of common stock
-
-
0
791,418
Net proceeds from option exercises
-
-
0
113,541
Net proceeds from note payable issuance related party-Nonrelated Party
-
-
300,000
-
Net proceeds from note payable issuance related party-Related Party
-
-
200,000
-
Net proceeds from warrant exercise
-
-
0
0
Net proceeds from notes payable issuance
675,000
500,000
-
-
Net cash provided by financing activities
675,000
500,000
500,000
904,959
Net increase (decrease) in cash
185,498
-285,119
34,149
198,443
Cash, beginning of period
263,827
548,946
514,797
283,714
Cash, end of period
449,325
263,827
548,946
514,797
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromnotes payable...$675,000 Net cash provided byfinancing activities$675,000 Net increase(decrease) in cash$185,498 (468.31%↑ Y/Y)Canceled cashflow$489,502 Accounts payable$177,865 (89.84%↑ Y/Y)Non-cash interestexpense$113,910 Stock-based compensation$41,490 (-2.48%↓ Y/Y)Prepaid expenses andother current assets-$27,187 (74.95%↑ Y/Y)Depreciation expense$26,198 (-31.78%↓ Y/Y)Accrued expenses$25,757 (16.26%↑ Y/Y)Vendor expense settledin shares$21,000 (40.00%↑ Y/Y)Amortization of operatinglease right of use...$19,402 (-44.41%↓ Y/Y)Net cash used ininvesting activities-$253,027 (-9.27%↓ Y/Y)Net cash provided by(used in) operating...-$236,475 (-189.51%↓ Y/Y)Canceled cashflow$452,809 Purchases of property andequipment$253,027 (9.27%↑ Y/Y)Accounts receivable, net$293,902 (246.75%↑ Y/Y)Net loss-$277,601 (80.11%↑ Y/Y)Deferred revenue-$77,941 (-105.47%↓ Y/Y)Inventory, net$20,981 (-14.34%↓ Y/Y)Operating leaseliabilities-$18,859 (42.15%↑ Y/Y)

Nuo Therapeutics, Inc. (AURX)

Nuo Therapeutics, Inc. (AURX)